Status:
RECRUITING
Multi-omics Study for Early Detection of Colorectal Cancer (MOED-CRC)
Lead Sponsor:
Zhejiang University
Collaborating Sponsors:
New Horizon Health Technology Co., Ltd
Conditions:
Colorectal Cancer
Adenomatous Polyps
Eligibility:
All Genders
18+ years
Brief Summary
The primary objective of the study is to screen multi-omics markers in blood samples and construct a prediction model for CRC based on liquid biopsy, and we will further optimize the prediction model ...
Detailed Description
This multicenter research intends to enroll 3,600 participants according to predefined inclusion and exclusion criteria. The study will be divided into two groups: the "cancer arm" and the "control ar...
Eligibility Criteria
Inclusion
- Inclusion Criteria for Case Arm:
- Aged over 18 years.
- Participants confirmed with colorectal adenocarcinoma or advanced adenoma through colonoscopy and pathological examination.
- Provision of informed consent prior to any study specific procedures, sampling, and analyses.
- Inclusion Criteria for Control Arm:
- Individuals of "General risk arm" should meet all the following criteria:
- No history of colorectal adenomas or sessile serrated polyps.
- No history of inflammatory bowel disease (8-10 years ).
- No family history (first-degree relatives) of colorectal cancer.
- Individuals of "High-risk arm" should meet at least one of the following criteria:
- Asia-Pacific Colorectal Screening (APC) score ≥ 3.
- Family history (first-degree relatives) of colorectal cancer.
- History of positive fecal occult blood test.
- Any 2 of the following: chronic diarrhea, chronic constipation, mucous bloody stools, history of psychological stimulation, history of chronic appendicitis or appendectomy, history of chronic biliary disease or cholecystectomy.
- Individuals with inflammatory bowel disease.
- All participants must be confirmed not to have colorectal malignancy or advanced adenomas through colonoscopy.
- Provision of informed consent prior to any study specific procedures, sampling, and analyses.
- Exclusion Criteria:
- History of other malignant tumors (excluding non-melanoma skin cancer).
- Prior or related treatments previously (including colorectal cancer or advanced adenoma surgery, endoscopic treatment, chemotherapy, targeted therapy, immunotherapy, radiation, neoadjuvant therapy, etc.).
- Patients with hereditary colorectal diseases (including Lynch syndrome, familial CRC type X (FCCX), familial adenomatous polyposis (FAP), MUTHY-associated polyposis (MAP), Peutz-Jeghers syndrome (PJS), juvenile polyposis syndrome (JPS), serrated polyposis syndrome (SPS), etc.).
- Usage of anti-tumor drugs such as methotrexate, cyclophosphamide, mercaptopurine, and bendamustine for other diseases within 30 days before blood collection.
- Prior blood transfusion (including blood components) within the past 2 weeks.
- Prior organ transplantation, bone marrow transplantation, or stem cell transplantation.
- Pregnancy women.
- Prior or current anti-infection treatment within 14 days before blood collection.
- Inability to comply with study procedures such as blood collection and related examinations.
- Deemed unsuitable for participation in the clinical trial by the investigator.
Exclusion
Key Trial Info
Start Date :
January 11 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2027
Estimated Enrollment :
3600 Patients enrolled
Trial Details
Trial ID
NCT06220617
Start Date
January 11 2024
End Date
June 30 2027
Last Update
January 30 2024
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
The Second Affiliated Hospital of Zhejiang University
Hangzhou, Zhejiang, China, 31000
2
Sun Yat-Sen University Cancer Hospital
Guangzhou, China
3
Yunnan cancer hospital
Kunming, China
4
Jiangsu province hospital
Nanjing, China